

Critical Reviews™ in Therapeutic Drug Carrier Systems

INDEX VOLUME 34, 2017

Page Range of Issues

Issue 1: 1-96; Issue 2: 97-183; Issue 3: 185-282; Issue 4: 283-386; Issue 5: 387-488; Issue 6: 489-587

ISSUE 1

Heparin-Tailored Biopolymeric Nanocarriers in Site-Specific Delivery: A Systematic Review <i>A. Garg, R. Sharma, V. Pandey, V. Patel, & A.K. Yadav</i>	1
Applications and Risks of Nanomaterials Used in Regenerative Medicine, Delivery Systems, Theranostics, and Therapy <i>E.I. Medina-Reyes, D. García-Viáculo, F.A. Carrero-Martínez, & Y.I. Chirino</i>	35
Lessons Learned from Gemcitabine: Impact of Therapeutic Carrier Systems and Gemcitabine's Drug Conjugates on Cancer Therapy <i>S. Dyawanapelly, A. Kumar, & M.K. Chourasia</i>	63

ISSUE 2

Rationalized Insights on Causes of Rheumatoid Arthritis in the Elderly and Women: Special Emphasis on Treatment Strategies <i>S. Srivastava, S. Patel, D. Singh, & M.R. Singh</i>	97
Supramolecular Delivery Systems for Non-Platinum Metal-Based Anticancer Drugs <i>P. Ringhieri, G. Morelli, & A. Accardo</i>	149

ISSUE 3

Three- and Four-Dimensional Spheroid and FiSS Tumoroid Cultures: Platforms for Drug Discovery and Development and Translational Research <i>R.R. Nair, S. Padhee, T. Das, R. Green, M. Howell, S.S. Mohapatra, & S. Mohapatra</i>	185
Stimuli-Responsive Systems with Diverse Drug Delivery and Biomedical Applications: Recent Updates and Mechanistic Pathways <i>B. Singh, R.K. Khurana, B. Garg, S. Saini, & R. Kaur</i>	209
Lipid Nanoparticles for Nasal/Intranasal Drug Delivery <i>S. Cunha, M.H. Amaral, J.M. Sousa Lobo, & A.C. Silva</i>	257

ISSUE 4

Liposome-Based Nanomedicine Therapeutics for Rheumatoid Arthritis <i>M. Rahman, S. Beg, F. Anwar, V. Kumar, R. Ubale, R.T. Addo, R. Ali, & S. Akhter</i>	283
Recent Advances in Nanoparticle-Based Targeted Drug-Delivery Systems against Cancer and Role of Tumor Microenvironment <i>U.A. Ashfaq, M. Riaz, E. Yasmeen, & M.Z. Yousaf</i>	317
Nanostructured Lipid Carriers: A New Paradigm in Topical Delivery for Dermal and Transdermal Applications <i>G. Sharma, K. Thakur, K. Raza, B. Singh, & O.P. Katare</i>	355

ISSUE 5

Emerging Trends in Therapeutic Algorithm of Chronic Wound Healers: Recent Advances in Drug Delivery Systems, Concepts-to-Clinical Application and Future Prospects	387
<i>M. Shao, Z. Hussain, H. Ei Thu, S. Khan, M. de Matas, V. Silkstone, H-Li. Qin, & S.N.A. Bukhari</i>	
A Review on Potential of Proteins as an Excipient for Developing a Nano-Carrier Delivery System	453
<i>A. Chakraborty & P. Dhar</i>	

ISSUE 6

Implication of Formulation Strategies on the Bioavailability of Selected Plant-Derived Hepatoprotectants	489
<i>R.P. Dash, M. Kala, M. Nivsarkar, & R.J. Babu</i>	
Clinical Success versus Attrition of Investigational Pharmaceuticals: A Vignette	527
<i>R. Gupta</i>	
Expanding the Domain of Drug Delivery for HIV Prevention: Exploration of the Transdermal Route	551
<i>A. Puri, A. Sivaraman, W. Zhang, M.R. Clark, & A.K. Banga</i>	

Critical Reviews™ in Therapeutic Drug Carrier Systems

AUTHOR INDEX VOLUME 34, 2017

Page Range of Issues

Issue 1: 1-96; Issue 2: 97-183; Issue 3: 185-282; Issue 4: 283-386; Issue 5: 387-488; Issue 6: 489-587

Accardo, A., 149	Garg, A., 1	Qin, H-Li., 387
Addo, R.T., 283	Garg, B., 209	Rahman, M., 283
Akhter, S., 283	Green, R., 185	Raza, K., 355
Ali, R., 283	Gupta, R., 527	Riaz, M., 317
Amaral, M.H., 257	Howell, M., 185	Ringhieri, P., 149
Anwar, F., 283	Hussain, Z., 387	Saini, S., 209
Ashfaq, U.A., 317	Kala, M., 489	Shao, M., 38
Babu, R.J., 489	Katare, O.P., 355	Sharma, G., 355
Banga, A.K., 551	Kaur, R., 209	Sharma, R., 1
Beg, S., 283	Khan, S., 387	Silkstone, V., 387
Bukhari, S.N.A., 387	Khurana, R.K., 209	Silva, A.C., 257
Carrero-Martínez, F.A., 35	Kumar, A., 63	Singh, B., 209, 355
Chakraborty, A., 453	Kumar, V., 283	Singh, D., 97
Chirino, Y.I., 35	Medina-Reyes, E.I., 35	Singh, M.R., 97
Chourasia, M.K., 63	Mohapatra, Shyam.S., 185	Sivaraman, A., 551
Clark, M.R., 551	Mohapatra, Subhra, 185	Sousa Lobo, J.M., 257
Cunha, S., 257	Morelli, G., 149	Srivastava, S., 97
Das, T., 185	Nair, R.R., 185	Thakur, K., 355
Dash, R.P., 489	Nivsarkar, M., 489	Ubale, R., 283
de Matas, M., 387	Padhee, S., 185	Yadav, A.K., 1
Dhar, P., 453	Pandey, V., 1	Yasmeen, E., 317
Dyawanaipelly, S., 63	Patel, S., 97	Yousaf, M.Z., 317
Ei Thu, H., 387	Patel, V., 1	Zhang, W., 551
García-Viacobo, D., 35	Puri, A., 551	

Critical Reviews™ in Therapeutic Drug Carrier Systems

SUBJECT INDEX VOLUME 34, 2017

Page Range of Issues

Issue 1: 1-96; Issue 2: 97-183; Issue 3: 185-282; Issue 4: 283-386; Issue 5: 387-488; Issue 6: 489-587

advanced therapies, 387	engineered nanomaterials, 35	nasal/intranasal
andrographolide, 489	enhancement, 551	administration, 257
anticancer agents, 1	enzymatic therapy, 97	natural polymers, 387
anticoagulants, 1	extracellular matrix (ECM),	nonlinear healing, 387
antitubercular drugs, 1	185	novel targeted system, 97
autoimmune disease, 97	fiber-inspired smart scaffold	pathogenesis, 97
bioactivity, 453	(FiSS), 185	pharmacokinetics, 489
bioavailability, 355, 453	Food and Drug	phyllanthin, 489
biocompatibility, 1,317, 435	Administration (FDA), 317	picroside, 489
biodegradability, 453	formulation, 489	polymeric particles, 149
biomedical applications, 35	gelling, 209	pre-exposure prophylaxis
biopsy-derived tumoroids	gemcitabine, 63	(PrEP), 551
(BdTs), 185	glycyrrhizin, 489	protein, 453
cancer, 317	heparin, 1	randomized controlled trial
cancer stem cells (CSCs),	hepatoprotective, 489	(RCT), 527
185	HIV prevention, 551	regenerative medicine, 35
cancer therapy, 63	hydrogels, 209	rheumatoid arthritis, 97, 283
case-control, 527	hypophyllanthin, 489	second generation lipidic
cationic liposomes, 283	intelligent polymers, 209	carriers, 355
chemical penetration, 551	kutkoside 489	silymarin, 489
chronic wounds, 387	lipoidal carriers, 355	smart polymers, 209
clinical approval, 527	liposomes, 149, 283	sol-to-gel, 209
cohort, 527	magnetoliposome, 283	stealth liposome, 283
complement activation-	metal-based drugs, 149	supramolecular aggregates,
related pseudo allergy	micelles, 149	149
(CARPA), 283	molecular imprinting, 209	synthetic polymers, 387
conventional dressing, 387	nanobiotechnology, 317	theranostic, 209
corticosteroids, 283	nanoparticle, 63	therapy, 35
cross sectional, 527	nanoparticles, 1, 257	transdermal, 355, 551
curcumin, 489	nanostructured lipid carriers	tumor microenvironment
dermal, 355	(NLCs), 257, 355	(TME), 185, 317
dimensional cultures, 185	nanotechnology, 317	uptake mechanism, 453
drug targeting, 283	nanotheranostics, 35	
efficacy upgradation, 387	nano-vehicle, 453	